Part D Overhaul: The Silver Lining Amid Very Dark Cloud Of US Drug Pricing Bill
Senate version of a potential drug pricing overhaul in the US includes one silver lining for manufacturers: a re-design and update of the Part D drug benefit. Is there any chance of extracting that item for the very dark clouds around it?
You may also be interested in...
The White House is playing up a new initiative to support ‘biotechnology and biomanufacturing.’ The focus on innovation is always a welcome theme – but it does not signal any change in the emphasis on cutting drug pricing in the Biden Administration.
Patient advocates are optimistic that ‘historic bill’ establishing price negotiation, inflation rebates and a spending cap in Medicare will pass into law.
Plan includes new 30% manufacturer discount in the US Medicare Part D catastrophic phase, which manufacturers will oppose as too high. But it also caps beneficiary cost sharing, a long-sought industry goal.